#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Current alternatives of pulmonary arterial hypertension treatment


Authors: H. Al-Hiti
Authors‘ workplace: Centrum pro diagnostiku a léčbu plicní hypertenze ;  Klinika kardiologie IKEM, Praha
Published in: Kardiol Rev Int Med 2005, 7(2): 90-94
Category: Editorial

Overview

Pulmonary arterial hypertension is a significant medical problem, when serious pulmonary vascular resistance leads to dysfunction, right ventricle failure and eventually to death. Author presents an overview of contemporary knowledge of pulmonary arterial hypertension treatment.

Keywords:
pulmonary arterial hypertension (PAH) – pulmonary vasoreactivity – therapy of PAH


Sources

1.Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327(2): 76-81.

2.Groves BM, Badesch DM, Turkevich D et al. Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension with efficacy of treatment with calcium channel blockers and survival. In: Weir K (ed). Ion flux in pulmonary vascular control. New York: Plenum Press 1993: 317-330.

3.Schrader BJ, Invar S, Kaufmann L et al. Comparison of the effect of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 1992; 29: 1060-1064.

4.Sitbon O, Hubert M, Jagot JL et al. Inhaled nitric oxide as a screening agent for safety identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: 265-270.

5.Opitz CF, Wensel R, Bettmann M et al. Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003; 24: 356-365.

6.Sitbon O, Hubert M, Ioos V et al. Who benefits from long-term calcium-channel blockers therapy in primary pulmonary hypertension? Am J Respir Crit Care Med 2003; 167: A440.

7.Frank H, Mlczoch, Huber K et al. The effect of anticoagulant therapy in primary and anorectic drug-included pulmonary hypertension. Chest 1997; 112(3): 714-421.

8.Sandoval J, Gaspar J, Pulido T et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilatator treatment. J Am Coll Cardiol 1998; 32: 297-304.

9.Hosenpud JD, Bennett L E et al. The registry of the International society for Heart and Lung Transplantation: Seventeenth official report 2000. J Heart Lung Transplant 2000; 19(10): 909-931.

10.Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334(5): 296-302.

11.Higenbottam T. Treatment of pulmonary hypertension by inhaled delivery. New York: The Parthenon Publishing Group 1999: 9-17.

12.Rubin LJ, Mendoza J, Hood M et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of

randomized trial. Ann Intern Med 1990; 112(7): 485-491.

13.Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum disease. A randomized, controlled trial. Ann Intern Med 2000; 132(6): 425-434.

14.McLaunghlin VV, Gaine SP, Barts RJ et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003; 41(2): 293-299.

15.Simonneau G, Barts RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertsion. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165(6): 800-804.

16.Okano Y, Yoshioka T, Schimouchi A et al. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997; 349(9062): 1365.

17.Galie N, Manes A, Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur Respir J 2002; 20(4): 1037-1049.

18.Saji T, Ozawa Y, Ishikita T et al. Short-term hemodynamic effects of new oral PGI 2 analogue, beraporost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996; 78(2): 244-247.

19.Nagaya N, Uematsu M, Okano Y et al. Effects of beraprost podium, an oral prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999; 34(4):1188-1192.

20.Galie N, Hubert M, Vachiery JL et al. Effect of beraprost sodium, an oral prostacyclin analogue, in patinets with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-1502.

21.Barts RJ, McGoon M, McLaughlin VV et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125.

22.Krause W, Krais T. Pharmacokinetics and phramacodynamics of the prostacyclin analogue iloprost in man. Rur J Clin Pharmacol 1986; 30(1): 61-68.

23.Hoeper MM, Olschewski H, Ghofrani HA et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH Study Group. J Am Coll Cardiol 2000; 35(1): 176-182.

24.Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002; 347(5): 322-329.

25.Hoeper MM, Schwarze M, Ehlerging S et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342(25): 1866-1870.

26.Yanagisawa M. The endothelin system. A new target for therapeutic intervention. Circulacion 1994; 89(3): 1320-1322.

27.Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346(16): 869-903.

28.Barts R, Langleben D, Frost A et al. Sitaxsentan, a selective ETA receptor antagonist, improves exercise capacity and NYHA functional class in pulmonary arterial hypertension (abstr). Am J Respir Crit Care Med 2003; 167: A440.

29.Barts R, Langleben D, Frost A et al. Sitaxsentan, a selective ETA receptor antagonist, improves cardiopulmonary hemodynamics in pulmonary hypertension (abstr). Am J Respir Crit Care Med 2003; 167: A273.

30.Rubin LJ, Galie N, Badesch BD et al. Ambisertan improves exercise capacity and clinical measures in pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2004. (v tisku)

31.Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000; 343(18): 343-1342.

32.Bhatia S, Frantz RP, Severson CJ et al. Immediate and long-term hemodynamic and clinical effects of sildenafil in patient with pulmonary arterial hypertension receiving vasodilaror therapy. Mayo Clin Proc 2003; 78(10): 1207-13.

33.Michelakis ED, Tymchak W, Noga M et al. Long- term treatment with oral sildenafil safe and improves functional capacity and hemodynamics in patient with pulmonary arterial hypertension. Circulation 2003; 108(17): 2006-2069.

34.Sastry BKS, Narasimhan C, Reddy NK et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo–controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43(7): 1149-1153.

35.Nagaya N. Short–term oral administration of L-arginin improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med 2001; 163(4): 887-891.

36.Hubert M, Barst R, Robbins I et al. Safety and efficacy of bosentan combined with epoprostenol in patients with severe pulmonary arterial hypertension (abstr). Am J Respir Crit Care Med 2003; 167: A441.

37.Ghofrani HA, Rose F, Schermuly RT et al. Oral sidenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42(1): 158-164.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#